- Home
- C vs NVO Comparison
C vs NVO Comparison
Compare C & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | C | NVO |
|---|---|---|
| Founded | 1812 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.7B | 172.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | C | NVO |
|---|---|---|
| Price | $105.82 | $38.13 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 11 |
| Target Price | ★ $124.50 | $51.00 |
| AVG Volume (30 Days) | 11.7M | ★ 18.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 2.20% | ★ 3.17% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.84 | N/A |
| Revenue Next Year | $3.86 | $3.30 |
| P/E Ratio | $16.63 | ★ $13.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $55.51 | $35.85 |
| 52 Week High | $125.16 | $82.23 |
Technical Indicators
Market Signals| Indicator | C | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 39.01 | 32.81 |
| Support Level | $92.68 | $35.85 |
| Resistance Level | $124.06 | $50.30 |
| Average True Range (ATR) | 3.79 | 0.90 |
| MACD | -0.51 | 0.31 |
| Stochastic Oscillator | 23.02 | 42.92 |
Price Performance
Historical ComparisonAbout C Citigroup Inc.
Citigroup is a global financial-services company doing business in more than 160 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.